In this issue:
Tisagenlecleucel for relapsed or refractory follicular lymphoma
Venetoclax + azacytidine for treatment-naïve AML
Nivolumab + brentuximab vedotin in relapsed/refractory cHL
Brentuximab vedotin + bendamustine for relapsed/refractory cHL
Venetoclax consolidation after fixed-duration venetoclax + obinutuzumab for CLL
Lisocabtagene maraleucel for relapsed/refractory CLL or SLL
Safety and efficacy BNT162b mRNA COVID-19 vaccine in CLL
Polatuzumab or CAR T-cell therapy for refractory/relapsed DLBCL
Sequential treatment with blinatumomab and inotuzumab in B-cell ALL
Total body irradiation + fludarabine myeloablative conditioning for ALL
Please login below to download this issue (PDF)